{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:41Z","timestamp":1791563141951,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.ackd.2010.10.003","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T04:05:35Z","timestamp":1294632335000},"page":"28-41","source":"Crossref","is-referenced-by-count":188,"title":["Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management"],"prefix":"10.1053","volume":"18","author":[{"given":"Peter N.","family":"Van Buren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2010.10.003_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/ajkd.2002.30542","article-title":"Hemodialysis associated hypertension: pathophysiology and therapy","volume":"39","author":"Horl","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2010.10.003_bib2","first-page":"S231","article-title":"Excerpts from the United States renal data system-2009 Annual Data Report: atlas of chronic kidney disease and end stage renal disease in the United States. Incidence and prevalence","volume":"55","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2010.10.003_bib3","first-page":"S35","article-title":"Excerpts from the United States Renal Data System-2009 Annual Data Report: atlas of chronic kidney disease and end stage renal disease in the United States. Chronic kidney disease in the NHANES population","volume":"55","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.10.003_bib4","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1093\/ndt\/13.10.2547","article-title":"Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy","volume":"13","author":"Schwartz","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 2","key":"10.1053\/j.ackd.2010.10.003_bib5","first-page":"S1","article-title":"KDOQI\u2122 Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"National Kidney Foundation","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.10.003_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ki.1992.118","article-title":"Prevalence and causes of albuminuria in non insulin-dependent diabetic patients","volume":"4","author":"Parving","year":"1992","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.HYP.19.5.403","article-title":"Diabetes mellitus and hypertension","volume":"19","author":"Epstein","year":"1992","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF00404089","article-title":"Prevalence of\u00a0hypertension in type 1 (insulin dependent) diabetes mellitus","volume":"33","author":"Norgaard","year":"1990","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2010.10.003_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmj.296.6616.156","article-title":"Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes","volume":"296","author":"Parving","year":"1988","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2010.10.003_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa013410","article-title":"Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes","volume":"347","author":"Lurbe","year":"2002","journal-title":"N Engl J\u00a0Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/diabetes.47.3.439","article-title":"Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients","volume":"47","author":"Fagerudd","year":"1998","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2010.10.003_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1523-1755.1999.00232.x","article-title":"Renal disease and hypertension in non-insulin dependent diabetes mellitus","volume":"55","author":"Ismail","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib13","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1681\/ASN.V7122627","article-title":"Renal findings in patients with short-term type 2 diabetes","volume":"7","author":"Keller","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.10.003_bib15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2215\/CJN.02560607","article-title":"Genetic factors in diabetic nephropathy","volume":"2","author":"Freedman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semnephrol.2007.01.004","article-title":"Mining the genome for susceptibility to diabetic nephropathy: the role of large-scale studies and consortia","volume":"27","author":"Iynegar","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib17","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI118623","article-title":"Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH\/NADPH oxidase activation","volume":"97","author":"Rajagopalan","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2010.10.003_bib18","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1681\/ASN.V10112382","article-title":"The paradox of the low renin state in diabetic nephropathy","volume":"10","author":"Price","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0895-7061(98)00265-9","article-title":"The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type 2 diabetes mellitus","volume":"12","author":"Price","year":"1999","journal-title":"Am J Hypertens"},{"issue":"4 Pt. 2","key":"10.1053\/j.ackd.2010.10.003_bib20","doi-asserted-by":"crossref","first-page":"F477","DOI":"10.1152\/ajprenal.1993.265.4.F477","article-title":"Renal rennin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations","volume":"265","author":"Anderson","year":"1993","journal-title":"Am J Renal Phys"},{"key":"10.1053\/j.ackd.2010.10.003_bib21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/ajkd.1998.v31.pm9469501","article-title":"Renal ACE immunohistochemical localization in NIDDM patients with nephropathy","volume":"31","author":"Mizuiri","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.10.003_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/diacare.29.04.06.dc05-1873","article-title":"Tissue gene expression of rennin-angiotensin system in human type 2 diabetic nephropathy","volume":"29","author":"Konoshita","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.0000205761.22353.5f","article-title":"Angiotensin-converting enzyme II in\u00a0the heart and kidney","volume":"98","author":"Danilcyzk","year":"2006","journal-title":"Circ Res"},{"key":"10.1053\/j.ackd.2010.10.003_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.HYP.0000060689.38912.CB","article-title":"Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy","volume":"41","author":"Tikellis","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/ki.1977.132","article-title":"Sodium, rennin, aldosterone, catecholamines, and blood pressure in diabetes mellitus","volume":"12","author":"De Chatel","year":"1977","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.107.090647","article-title":"Role of glomerular filtration rate in controlling blood pressure early in diabetes","volume":"52","author":"Brands","year":"2008","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0002-9343(90)90144-3","article-title":"Salt sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus","volume":"88","author":"Tuck","year":"1990","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2337\/diacare.24.1.111","article-title":"sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients","volume":"24","author":"Imanishi","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00252649","article-title":"The effect of insulin on renal sodium metabolism","volume":"21","author":"DeFronzo","year":"1981","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2010.10.003_bib30","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.HYP.7.5.714","article-title":"Soidum balance in renal failure: a comparison of patients with normal subjects under extremes of sodium intake","volume":"7","author":"Koomans","year":"1985","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/01.HYP.31.5.1083","article-title":"Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells","volume":"31","author":"Gu","year":"1998","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2337\/diacare.17.6.578","article-title":"Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients","volume":"17","author":"Spallone","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1464-5491.1991.tb01625.x","article-title":"Twenty-four hour blood pressure and heart rate profiles of diabetic patients with abnormal cardiovascular reflexes","volume":"8","author":"Liniger","year":"1991","journal-title":"Diabetic Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1464-5491.1999.00127.x","article-title":"Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy","volume":"16","author":"Nielsen","year":"1999","journal-title":"Diabetic Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0895-7061(96)87747-8","article-title":"Enhanced sympathetic nervous system activity: the linchpin between insulin resistance, hyperinsulinemia, and heart rate","volume":"9","author":"Facchini","year":"1996","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2010.10.003_bib36","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/01.ATV.0000081742.92006.59","article-title":"Asymetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethyl dimethylaminohydrolase","volume":"23","author":"Achan","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ackd.2010.10.003_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0002-9149(01)02063-X","article-title":"Plasma concentrations of asymetric dimethylarginine are increased in patients with type 2 diabetes mellitus","volume":"88","author":"Abbasi","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ackd.2010.10.003_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.V103594","article-title":"Asymetric dimethylarginine concentrations differ in patients with end stage renal disease: relationship to treatment method and atherosclerotic disease","volume":"10","author":"Kielstein","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib39","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with\u00a0end-stage renal disease: a prospective study","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2010.10.003_bib40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/diacare.27.3.765","article-title":"Elevated plasma asymetric dimethylarginine as a marker of cardiovascular morbidity in early\u00a0diabetic nephropathy in type 1 diabetes","volume":"27","author":"Tarnow","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib41","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1681\/ASN.2005121379","article-title":"Molecular mechanism for elevation of asymetric dimethylarginine and its role for hypertension in chronic kidney disease","volume":"17","author":"Matsuguma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MCO.0b013e32819f8ecd","article-title":"Insulin action and insulin resistance in vascular endothelium","volume":"10","author":"Muniyappa","year":"2007","journal-title":"Curr Opin Nutr Metab Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib43","first-page":"159","article-title":"Plasma endothelin levels in\u00a0NIDDM patients with macroangiopathy","volume":"25","author":"Donatelli","year":"1994","journal-title":"Diabetes Res"},{"key":"10.1053\/j.ackd.2010.10.003_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(89)92631-7","article-title":"Plasma endothelin levels in patients with uremia","volume":"1","author":"Koyama","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2010.10.003_bib45","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/ndt\/gfm364","article-title":"Hemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease","volume":"22","author":"Dhaun","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2010.10.003_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2004.04.005","article-title":"Role of nitric oxide in diabetic nephropathy","volume":"24","author":"Prabhakar Sharma","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib47","first-page":"E762","article-title":"Nitric Oxide may be required to prevent hypertension at the onset of diabetes","volume":"279","author":"Fitzgerald","year":"2000","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ackd.2010.10.003_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.ackd.2010.10.003_bib49","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1053\/ajkd.2001.29280","article-title":"Oxidative stress and inflammation in hemodialysis patients","volume":"38","author":"Spittle","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2010.10.003_bib50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0891-5849(96)00233-X","article-title":"Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure","volume":"21","author":"Ceballos-Picot","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib51","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1046\/j.1523-1755.1998.00947.x","article-title":"Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension","volume":"53","author":"Vaziri","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib52","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1681\/ASN.2006080895","article-title":"Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production","volume":"18","author":"Prabhakar","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib53","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.RES.74.6.1141","article-title":"Angiotensin II stimulates NADH and NADPH activity in cultured vascular smooth muscle cells","volume":"74","author":"Griendling","year":"1994","journal-title":"Circ Res"},{"key":"10.1053\/j.ackd.2010.10.003_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.HYP.0000203826.15076.4b","article-title":"Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy","volume":"47","author":"Ogawa","year":"2006","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib55","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.CIR.0000051459.74466.46","article-title":"Endothelin 1 increases vascular superoxide via endothelin a-NADPH oxidase pathway in low renin hypertension","volume":"107","author":"Li","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2010.10.003_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00000441-200106000-00005","article-title":"Impaired autoregulation: implications for the genesis of hypertension and hypertension induced renal injury","volume":"321","author":"Palmer","year":"2001","journal-title":"Am J Med Sci"},{"key":"10.1053\/j.ackd.2010.10.003_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/01.HYP.0000075949.19968.EF","article-title":"GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury","volume":"42","author":"Gnudi","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib58","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.2337\/diacare.25.2007.S82","article-title":"Diabetic nephropathy","volume":"25","author":"American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib59","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/bmj.285.6343.685","article-title":"Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy","volume":"285","author":"Mogensen","year":"1982","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2010.10.003_bib60","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bmj.294.6585.1443","article-title":"Effect of antihypertensive treatment on kidney function in diabetic nephropathy","volume":"294","author":"Parving","year":"1987","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2010.10.003_bib61","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(83)92462-5","article-title":"Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy","volume":"321","author":"Parving","year":"1983","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2010.10.003_bib62","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.1523-1755.2001.00790.x","article-title":"Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients","volume":"60","author":"Parving","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib66","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib67","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib68","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1097\/01.hjh.0000378896.82588.5c","article-title":"Prevention of microalbuminuria in type 2 diabetes (roadmap trial)","volume":"28","author":"Haller","year":"2010","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2010.10.003_bib69","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib70","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib71","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angiotensin II receptor blocker to a maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib72","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ace inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib73","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1046\/j.1523-1755.2003.00940.x","article-title":"Dual blockade of the rennin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy","volume":"63","author":"Jacobsen","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/diacare.28.2.273","article-title":"Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study","volume":"28","author":"Andersen","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2010.10.003_bib75","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib76","unstructured":"Department of Veterans Affairs; Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy VA NEPHRON-D Study: Nephropathy iN Diabetes Study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2010 Oct 26]. Available from: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00555217 NLM Identifier NCT00555217."},{"key":"10.1053\/j.ackd.2010.10.003_bib77","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2010.10.003_bib78","first-page":"S17","article-title":"Widespread distribution of human chymase","volume":"12","author":"Urata","year":"1994","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2010.10.003_bib79","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","article-title":"Time course of the antiproteinuric and antihypertensive effects of the direct rennin inhibition in type 2 diabetes","volume":"73","author":"Persson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib80","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib81","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria","volume":"32","author":"Persson","year":"2009","journal-title":"Diabetes Care"},{"key":"#cr-split#-10.1053\/j.ackd.2010.10.003_bib82.1","unstructured":"Novartis; Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2010 Oct 26]. Available from http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00549757;"},{"key":"#cr-split#-10.1053\/j.ackd.2010.10.003_bib82.2","unstructured":"NLM identifier 00549757."},{"key":"10.1053\/j.ackd.2010.10.003_bib83","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib84","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the rennin angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2010.10.003_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib86","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","article-title":"Beneficial impact of spironolactone in diabetic nephropathy","volume":"68","author":"Schjoedt","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib87","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephritic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2010.10.003_bib88","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blocker or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib89","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J\u00a0Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib90","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jama.291.3.335","article-title":"Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes","volume":"291","author":"Saydah","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2010.10.003_bib92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/qjmed\/hch039","article-title":"Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy","volume":"97","author":"Joss","year":"2004","journal-title":"QJM"},{"key":"10.1053\/j.ackd.2010.10.003_bib93","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib94","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood pressure control in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib95","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on\u00a0progression of diabetic nephropathy","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Int Med"},{"key":"10.1053\/j.ackd.2010.10.003_bib96","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1681\/ASN.2008070667","article-title":"Lowering blood pressure reduces renal events in type 2 diabetes","volume":"20","author":"De Galan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2010.10.003_bib97","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2010.10.003_bib98","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","article-title":"Thiazide diuretics, potassium, and the development of diabetes: a quantitative review","volume":"48","author":"Zillich","year":"2006","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2010.10.003_bib99","unstructured":"Van Buren PN, Huet-Adams B, Toto R. Effective antihypertensive therapies in high risk patients with diabetic nephropathy. J Investig Med. In press."},{"key":"10.1053\/j.ackd.2010.10.003_bib100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-148-1-200801010-00190","article-title":"Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease","volume":"148","author":"Kunz","year":"2008","journal-title":"Ann Int Med"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510001552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559510001552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T18:23:26Z","timestamp":1712082206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559510001552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S1548559510001552"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2010.10.003","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}